GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update

GT Biopharma, Inc. (NASDAQ:GTBP) was the target of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 90,000 shares, an increase of 556.9% from the December 31st total of 13,700 shares. Approximately 4.6% of the company’s shares are short sold. Based on an average daily volume of 365,300 shares, the days-to-cover ratio is presently 0.2 days.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on GTBP. Roth Capital raised shares of GT Biopharma to a “strong-buy” rating in a research note on Monday, December 2nd. Roth Mkm assumed coverage on GT Biopharma in a research report on Monday, December 2nd. They set a “buy” rating and a $11.00 price objective on the stock.

GT Biopharma Price Performance

Shares of GT Biopharma stock opened at $2.11 on Thursday. GT Biopharma has a 12 month low of $1.72 and a 12 month high of $10.66. The business has a fifty day simple moving average of $2.68 and a two-hundred day simple moving average of $2.53.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.